Cargando…
Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
PURPOSE: The capacity of nadir CA-125 levels to predict the prognosis of epithelial ovarian cancer remains controversial. This study aimed to explore whether the nadir CA-125 serum levels could predict the durations of overall survival (OS) and progression free survival (PFS) in patients with high-g...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644248/ https://www.ncbi.nlm.nih.gov/pubmed/23618037 http://dx.doi.org/10.1186/1757-2215-6-31 |
_version_ | 1782268437995716608 |
---|---|
author | Xu, Xia Wang, Yan Wang, Fang Jia, Lizhou Zhou, Yiqin Deng, Fei Qu, Junwei Zhou, Bifang Meng, Aifeng Fu, Bole Chen, Xiaoxiang Qian, Zhiying Wang, Jinhua |
author_facet | Xu, Xia Wang, Yan Wang, Fang Jia, Lizhou Zhou, Yiqin Deng, Fei Qu, Junwei Zhou, Bifang Meng, Aifeng Fu, Bole Chen, Xiaoxiang Qian, Zhiying Wang, Jinhua |
author_sort | Xu, Xia |
collection | PubMed |
description | PURPOSE: The capacity of nadir CA-125 levels to predict the prognosis of epithelial ovarian cancer remains controversial. This study aimed to explore whether the nadir CA-125 serum levels could predict the durations of overall survival (OS) and progression free survival (PFS) in patients with high-grade serous ovarian cancer (HG-SOC) from the USA and PRC. MATERIALS AND METHODS: A total of 616 HG-SOC patients from the MD Anderson Cancer Center (MDACC, USA) between 1990 and 2011 were retrospectively analyzed. The results of 262 cases from the Jiangsu Institute of Cancer Research (JICR, PRC) between 1992 and 2011 were used to validate the MDACC data. The CA-125 immunohistochemistry assay was performed on 280 tissue specimens. The Cox proportional hazards model and the log-rank test were used to assess the associations between the clinicopathological characteristics and duration of survival. RESULTS: The nadir CA-125 level was an independent predictor of OS and PFS (p < 0.01 for both) in the MDACC patients. Lower nadir CA-125 levels (≤10 U/mL) were associated with longer OS and PFS (median: 61.2 and 16.8 months with 95% CI: 52.0–72.4 and 14.0–19.6 months, respectively) than their counterparts with shorter OS and PFS (median: 49.2 and 10.5 months with 95% CI: 41.7–56.7 and 6.9–14.1 months, respectively). The nadir CA-125 levels in JICR patients were similarly independent when predicting the OS and PFS (p < 0.01 for both). Nadir CA-125 levels less than or equal to 10 U/mL were associated with longer OS and PFS (median: 59.9 and 15.5 months with 95% CI: 49.7–70.1 and 10.6–20.4 months, respectively), as compared with those more than 10 U/mL (median: 42.0 and 9.0 months with 95% CI: 34.4–49.7 and 6.6–11.2 months, respectively). Baseline serum CA-125 levels, but not the CA-125 expression in tissues, were associated with the OS and PFS of HG-SOC patients in the MDACC and JICR groups. However, these values were not independent. Nadir CA-125 levels were not associated with the tumor burden based on second-look surgery (p = 0.09). Patients who achieved a pathologic complete response had longer OS and PFS (median: 73.7 and 20.7 months with 95% CI: 63.7–83.7 and 9.5–31.9 months, respectively) than those with residual tumors (median: 34.6 and 10.6 months with 95% CI: 6.9–62.3 and 4.9–16.3 months, respectively). CONCLUSIONS: The nadir CA-125 level was an independent predictor of OS and PFS in HG-SOC patients. Further prospective studies are required to clinically optimize the chances for a complete clinical response of HG-SOC cases with higher CA-125 levels (>10 U/mL) at the end of primary treatment. |
format | Online Article Text |
id | pubmed-3644248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36442482013-05-05 Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer Xu, Xia Wang, Yan Wang, Fang Jia, Lizhou Zhou, Yiqin Deng, Fei Qu, Junwei Zhou, Bifang Meng, Aifeng Fu, Bole Chen, Xiaoxiang Qian, Zhiying Wang, Jinhua J Ovarian Res Research PURPOSE: The capacity of nadir CA-125 levels to predict the prognosis of epithelial ovarian cancer remains controversial. This study aimed to explore whether the nadir CA-125 serum levels could predict the durations of overall survival (OS) and progression free survival (PFS) in patients with high-grade serous ovarian cancer (HG-SOC) from the USA and PRC. MATERIALS AND METHODS: A total of 616 HG-SOC patients from the MD Anderson Cancer Center (MDACC, USA) between 1990 and 2011 were retrospectively analyzed. The results of 262 cases from the Jiangsu Institute of Cancer Research (JICR, PRC) between 1992 and 2011 were used to validate the MDACC data. The CA-125 immunohistochemistry assay was performed on 280 tissue specimens. The Cox proportional hazards model and the log-rank test were used to assess the associations between the clinicopathological characteristics and duration of survival. RESULTS: The nadir CA-125 level was an independent predictor of OS and PFS (p < 0.01 for both) in the MDACC patients. Lower nadir CA-125 levels (≤10 U/mL) were associated with longer OS and PFS (median: 61.2 and 16.8 months with 95% CI: 52.0–72.4 and 14.0–19.6 months, respectively) than their counterparts with shorter OS and PFS (median: 49.2 and 10.5 months with 95% CI: 41.7–56.7 and 6.9–14.1 months, respectively). The nadir CA-125 levels in JICR patients were similarly independent when predicting the OS and PFS (p < 0.01 for both). Nadir CA-125 levels less than or equal to 10 U/mL were associated with longer OS and PFS (median: 59.9 and 15.5 months with 95% CI: 49.7–70.1 and 10.6–20.4 months, respectively), as compared with those more than 10 U/mL (median: 42.0 and 9.0 months with 95% CI: 34.4–49.7 and 6.6–11.2 months, respectively). Baseline serum CA-125 levels, but not the CA-125 expression in tissues, were associated with the OS and PFS of HG-SOC patients in the MDACC and JICR groups. However, these values were not independent. Nadir CA-125 levels were not associated with the tumor burden based on second-look surgery (p = 0.09). Patients who achieved a pathologic complete response had longer OS and PFS (median: 73.7 and 20.7 months with 95% CI: 63.7–83.7 and 9.5–31.9 months, respectively) than those with residual tumors (median: 34.6 and 10.6 months with 95% CI: 6.9–62.3 and 4.9–16.3 months, respectively). CONCLUSIONS: The nadir CA-125 level was an independent predictor of OS and PFS in HG-SOC patients. Further prospective studies are required to clinically optimize the chances for a complete clinical response of HG-SOC cases with higher CA-125 levels (>10 U/mL) at the end of primary treatment. BioMed Central 2013-04-25 /pmc/articles/PMC3644248/ /pubmed/23618037 http://dx.doi.org/10.1186/1757-2215-6-31 Text en Copyright © 2013 Xu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Xu, Xia Wang, Yan Wang, Fang Jia, Lizhou Zhou, Yiqin Deng, Fei Qu, Junwei Zhou, Bifang Meng, Aifeng Fu, Bole Chen, Xiaoxiang Qian, Zhiying Wang, Jinhua Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
title | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
title_full | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
title_fullStr | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
title_full_unstemmed | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
title_short | Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer |
title_sort | nadir ca-125 level as prognosis indicator of high-grade serous ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644248/ https://www.ncbi.nlm.nih.gov/pubmed/23618037 http://dx.doi.org/10.1186/1757-2215-6-31 |
work_keys_str_mv | AT xuxia nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT wangyan nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT wangfang nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT jializhou nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT zhouyiqin nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT dengfei nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT qujunwei nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT zhoubifang nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT mengaifeng nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT fubole nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT chenxiaoxiang nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT qianzhiying nadirca125levelasprognosisindicatorofhighgradeserousovariancancer AT wangjinhua nadirca125levelasprognosisindicatorofhighgradeserousovariancancer |